Source: International Congress 2018 – Basic pharmacology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Nishiya (Tokyo, Japan), T. Honda (Tokyo, Japan), K. Itokawa (Tokyo, Japan), O. Ando (Tokyo, Japan), M. Suzuki (Tokyo, Japan), K. Morimoto (Tokyo, Japan). ADME properties of a novel PI3Kd inhibitor, DS-1515, in preclinical studies. 1053

Member's Comments

No comment yet.

Related content which might interest you: Pharmacological properties of a novel PI3Kd inhibitor, DS-1515 Source: International Congress 2018 – Basic pharmacology Year: 2018 Nonclinical safety profiles of DS-1515, a novel oral PI3Kd inhibitor. Source: International Congress 2018 – Basic pharmacology Year: 2018 In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 The pharmacological and safety profile of a novel selective phosphodiesterase-4(PDE4) inhibitor:- GRC- 3886 Source: Eur Respir J 2004; 24: Suppl. 48, 220s Year: 2004 Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Late-breaking abstract: Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011 In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilast Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 Efficacy of a novel PI3Kd inhibitor, DS-1515 in animal models of asthma Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018 In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agent Source: Annual Congress 2010 - Models of airways disease Year: 2010 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Systems biology, animal models and drug discovery Source: Annual Congress 2008 - “Omics” and systems biology: the promise of future disease understanding Year: 2008 From anti-PD1/L1 inhibitors to new immunotherapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 ‘Total PDE4 inhibitory activity‘: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006 CFTR correctors and potentiators: pre-clinical studies in mouse models for CF Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009 In vivo pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-α converting enzyme and matrix metalloproteinases, in models of airway inflammation Source: Eur Respir J 2002; 20: Suppl. 38, 169s Year: 2002 In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Identification of mechanism-specific biomarkers to guide development of the lung-selective inhaled pan-JAK inhibitor TD-8236 Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020